Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F, Chen B, Yang X, Wang H, Zhang G, Wang Y, Wang Y, Zhang N, Xue J, Long J, Li Y, Sun H, Xun Z, Liu K, Chen X, Song Y, Yang X, Lu Z, Mao Y, Sang X, Lu Y, Zhao H.
Xie F, et al.
Front Immunol. 2022 Dec 9;13:1052937. doi: 10.3389/fimmu.2022.1052937. eCollection 2022.
Front Immunol. 2022.
PMID: 36569829
Free PMC article.